Related Experiment Videos
Anticholinergic Drug Burden and Postoperative Delirium: A Systematic Review and Meta-Analysis
Yin-Sheng Liao1, Shi-Jian Liu1, Jian-Li Song1
1Departments of Anesthesiology, Zigong Fourth People's Hospital, Zigong, Sichuan, P.R. China.
Introduction:
Postoperative delirium (POD) is an important postoperative neurocognitive complication, and cumulative anticholinergic drug burden (ADB) may increase its risk by impairing central cholinergic neurotransmission. This systematic review and meta-analysis aimed to clarify the overall association between ADB scores and POD risk in adult surgical patients.
Methods:
We searched major databases and trial registries through February 2026 for studies that assessed ADB using validated scales and reported POD outcomes in adult surgical patients. Random-effects models pooled SMDs and ORs. Prespecified subgroup and sensitivity analyses explored heterogeneity and robustness. Risk of bias was assessed using NOS, and evidence certainty was rated using GRADE.
Results:
Ten reports from nine independent cohorts comprising 10,457 participants were included. Patients with POD had higher ADB scores than those without POD (SMD = 0.31, 95% CI: 0.20-0.43). Each one-point increase in continuous ADB was associated with 22% higher odds of POD (OR = 1.22, 95% CI: 1.09-1.37). Both low-to-moderate and high burden were associated with increased POD risk. In scale-specific analyses, the association was significant for ACB. The association was attenuated in studies that excluded patients with cognitive impairment. Methodological quality ranged from moderate to high, and certainty of evidence was low.
Conclusions:
Higher ADB is significantly associated with higher odds of POD, with a graded increase in risk across burden levels. Baseline cognitive impairment appears to amplify this association. These findings support preoperative ADB assessment and medication optimization in vulnerable surgical patients, while highlighting the need for prospective head-to-head comparisons of anticholinergic burden scales.
Registration:
PROSPERO (CRD420261294941).
Related Concept Videos
Indirect-Acting Cholinergic Agonists: Pharmacological Actions
At the neuromuscular junction, these agents work by inhibiting the breakdown of acetylcholine, allowing it to remain bound to the receptor and bind to nearby receptors. This process leads to repetitive firing of the endplate, causing muscle...
Direct-Acting Cholinergic Agonists: Pharmacokinetics
Direct-Acting Cholinergic Agonists: Therapeutic Uses
Depolarizing Blockers: Pharmocokinetics
Skeletal Muscle Relaxants: Adverse Effects
Unlike...
Cholinergic Antagonists: Therapeutic Uses
Respiratory Tract: Ipratropium, aclidinium, and tiotropium treat asthma, chronic bronchitis, and chronic obstructive pulmonary disease (COPD). They protect against bronchoconstriction caused by irritants like cigarette smoke, sulfur dioxide, and ozone. They also help reduce nasopharyngeal secretions in common...